Related Experiment Video
Updated: Aug 6, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Cystinosis metabolic bone disease: inflammatory profile in human peripheral blood mononuclear cells and derived
Candide Alioli1, Marcella Greco2, Marie-Noëlle Méaux1,3
1Pathophysiology, Diagnosis and Treatments of Bone Diseases, INSERM UMR1033, Lyon, France.
Insights
Cystinosis metabolic bone disease involves inflammation in patient cells, with increased IL-1 Receptor in osteoclasts. This suggests targeted anti-inflammatory therapies could help manage bone complications in cystinosis patients.
Area of Science:
- Biochemistry
- Immunology
- Pediatric Nephrology
Background:
- Cystinosis metabolic bone disease (CMBD) presents with bone pain, fractures, and deformities in patients with cystinosis, but its mechanisms are unclear.
- Blocking IL-1β signaling is a potential therapeutic strategy for muscular wasting in cystinosis.
Purpose of the Study:
- To investigate the pro-inflammatory profile of osteoclastic lineage in cystinotic patients.
- To explore the expression of inflammatory markers in peripheral blood mononuclear cells (PBMCs) and differentiated osteoclasts.
Main Methods:
- Collected blood samples from 14 cystinotic patients and 10 healthy controls.
- Isolated PBMCs and analyzed inflammatory marker gene expression using RT-qPCR.
- Differentiated PBMCs into osteoclasts to assess receptor expression.
Main Results:
- Significantly increased expression of IL-6, IL-8, CXCR3, and CCL2/MCP-1 in PBMCs from cystinotic patients.
- Elevated IL-1 Receptor expression in osteoclasts derived from cystinotic patients, but not IL-6 receptor.
Conclusions:
- Cystinotic patients exhibit an inflammatory profile in PBMCs and osteoclastic cells.
- Increased CXCR3 and MCP-1 may drive macrophage migration and activation, potentially explaining increased osteoclastogenesis.
- Osteoclastic IL-1 Receptor overexpression supports blocking IL-1β signaling as a therapeutic avenue for cystinosis complications.
Abstract:
Cystinosis metabolic bone disease (CMBD) is an emerging concept in infantile nephropathic cystinosis, patients presenting with bone pains, fractures, and deformations during teenage or early adulthood. The underlying mechanisms remain unclear. Our aim was to explore the pro-inflammatory profile of osteoclastic lineage in cystinotic patients. We obtained blood samples from 14 cystinotic patients and 10 pediatric healthy controls. Peripheral blood mononuclear cells (PBMCs) were isolated and used to explore by RT-qPCR the transcript expression of 8 inflammatory markers (Il-6, Il-8, Il-1β, CXCL1, CCL2/MCP-1, CXCR3, Il-1 Receptor, Il-6 Receptor). In addition, when possible, PBMCs were differentiated into osteoclasts for further experiments. The expression of Il-6, IL-8, CXCR3, and CCL2/MCP-1 was significantly increased in PBMCs from cystinotic patients. We also explored the expression of Il-1 Receptor and Il-6 Receptor, two major pro-osteoclastic signal inducers, in osteoclasts differentiated from PBMCs from controls (N = 3) and patients (N = 4). The expression of IL-1 Receptor (but not IL-6 receptor) was increased in osteoclasts obtained from cystinotic patients.
Conclusion:
There is an inflammatory profile in PBMCs and osteoclastic lineage in cells obtained from cystinotic patients. CXCR3 and MCP-1 stimulate migration and activation of macrophages, that may explain the previously reported local increased osteoclastogenesis. The osteoclastic overexpression of IL-1 Receptor is a relevant observation in the field since blocking Il-1β signaling has recently been proposed as a novel therapeutic approach to improve muscular wasting in this orphan disease.
What Is Known:
• Cystinosis metabolic bone disease (CMBD), an emerging concept with unclear underlying mechanisms, induces bone pains, fractures and deformations in patients with cystinosis. • Blocking Il-1β signaling may be a novel therapeutic approach to improve muscular wasting in cystinosis.
What Is New:
• There is an inflammatory profile in PBMCs and osteoclastic lineage in cells obtained from cystinotic patients, with an over-expression of IL-1 Receptor in osteoclasts. • We provide another experimental rationale to propose targeted anti-inflammatory therapies in cystinotic patients with severe bone disease.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...